Alterity Therapeutics Ltd ADR ATHE

$2.23 +0.06 (2.93%)

Valuation

Market cap
39,333,000
Revenue TTM
$0
Net income TTM
$-15,880,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,700
Avg volume
22,750
Day's range
$2.16 – $2.26
Shares out
18,126,000
Stochastic %K
35%
Beta
0.27
Analysts
Strong Sell
Price target
$11.75

Price

Company profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to tr...

Show more

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9349 4906
Website
https://alteritytherapeutics.com
Address
500 Collins Street, Level 15, Melbourne, Australia

Latest news

Stocktwits

GA09 Oct 30, 12:20 PM
$ATHE The following paragraphs sums up their position. Key words are "continues to evaluate", "ongoing discussions with a number of pharmaceutical companies", "progressing", "assistance of external advisor". These are constructive statements being used. They are not simply saying they are considering or looking into partnership opportunities but rather they continue to stay engaged in ongoing discussions which is constructive. I think they prefer a partnership over dilution because CEO did mention in the October Fireside Chat that they are not supportive of dilution because of Management's "angst" towards issuing more shares.
1 replies
Double__Down Oct 30, 10:27 AM
$ATHE
1 replies
BrokersNY Oct 30, 9:59 AM
$ATHE cash flow report not bad..
0 replies
GA09 Oct 28, 2:10 PM
$ATHE ATHE is scheduled to release earnings today pre market. Do we know if they released their earnings?
1 replies
Double__Down Oct 28, 1:55 AM
$ATHE
0 replies
GA09 Oct 23, 1:56 PM
$ATHE On the positive side, CEO stated they continue to have "ongoing discussions" & "new prospective partners" are also speaking to ATHE & CEO and the Management Team is aware of the dilution risk to existing shareholders if they go the capital raise route. He said they are looking at multiple approaches and they will only agree on a partnership if that partner is willing to develop 434 along with them and support them (fully) through out the process and not simply finance the trial only to drop off later and for ATHE to do a capital raise (in between the trial) and dilute the existing shareholders. He also said they have sufficient capital for the "initial phase of the trial" which means they know that the trial will be costly and they will (eventually) need funding for the full trial which is why they are looking at a potential partnership structure. Wall Street is not confident they find a partner given the sell off in the stock price. CEO has to prove them wrong soon!!!!
0 replies
GA09 Oct 23, 1:06 PM
$ATHE I listened to the Fireside Chat (this morning) & CEO was asked about plans for financing the Phase 3 trial. He did say they are getting new prospective partners and continuing to have discussions BUT they are also looking at a capital raise (which he admitted was a concern to existing shareholders due to dilution) only if the partner does not provide the value they are looking for in advancing 434 to ultimately being approved by the FDA. He said they are not simply looking for a partner to finance the Phase 3 trial but a strategic partner that is going to bring value to 434. It appears (so far) the partners are not offering the strategic value ATHE is looking for in a partner. Honestly, CEO did not seem optimistic on securing a partner (given his tone) BUT he is also not in support for a capital raise causing dilution. He did say they are still having "ongoing discussions" with potential partners. The partner should be "thoughtful development partner" & not simply a finance.
0 replies
GA09 Oct 23, 12:48 PM
$ATHE Three 6-K filed with the SEC. Are they issuing shares? Is this a dilution? Does anyone know? Thanks!
1 replies